Showing results (411-420 of 500) with videos related to
Sort By:
Pageof 50
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium studyVinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.Journal for Immunotherapy of Cancer|July 3, 2021
Systematic review of combinations of targeted or immunotherapy in advanced solid tumorsAaron C Tan, Stephen J Bagley, Patrick Y Wen, et al.Neuro-Oncology|May 20, 2024
Towards consistency in pediatric brain tumor measurements: Challenges, solutions, and the role of artificial intelligence-based segmentationAriana M Familiar, Anahita Fathi Kazerooni, Arastoo Vossough, et al.Neuro-Oncology Advances|December 8, 2020
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma WorkshopMarta Penas-Prado, Jing Wu, Daniel P Cahill, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.Journal of Neuro-Oncology|October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiformeMorris D Groves, Vinay K Puduvalli, Susan M Chang, et al.Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.Neuro-Oncology|February 23, 2011
DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expressionShichun Zheng, E Andres Houseman, Zachary Morrison, et al.Pageof 50